Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.

ABSTRACT:

Background

Women treated for breast cancer (BC) often suffer genitourinary syndrome of menopause. These symptoms may be alleviated by vaginal estrogen therapy (VET) or menopausal hormone therapy (MHT). However, there are concerns of risks of recurrence of BC and death following treatment.

Methods

Our study included longitudinal data from a national cohort of postmenopausal women, diagnosed 1997-2004 with early-stage invasive estrogen receptor-positive nonmetastatic BC, who received no treatment or 5 years of adjuvant endocrine therapy. We ascertained prescription data on hormone therapy, VET or MHT, from a national prescription registry. We evaluated mortality and risk of recurrence associated with use of VET and MHT vs non-use using multivariable models adjusted for potenti

SUBMITTER: Cold S 

PROVIDER: S-EPMC9552278 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature